Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Connect Biopharma reported positive topline results from its global Phase 2 trial of CBP-201 for adult patients with moderate-to-severe atopic dermatitis. The trial met its primary endpoint, showing statistically significant Eczema Area and Severity Index (EASI) score reductions across all treatment arms compared to placebo. Key secondary endpoints also demonstrated efficacy. CBP-201 exhibited a favorable safety profile with low incidence of adverse events. The Company plans to initiate a Phase 3 trial program in mid-2022 to further explore the therapeutic potential of CBP-201.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that CEO Dr. Zheng Wei and Chief Business Officer Dr. Selwyn Ho will participate in fireside chats at two healthcare conferences.
- Jefferies London Healthcare Conference: Available on-demand from November 18 at 8:00 a.m. GMT.
- 33rd Annual Piper Sandler Healthcare Conference: Available on-demand from November 22 at 10:00 a.m. ET.
Webcasts will be accessible on the Company’s Investor Relations page. Connect Biopharma focuses on therapies for chronic inflammatory diseases, with product candidates targeting conditions like atopic dermatitis and ulcerative colitis.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that Dr. Zheng Wei, CEO, and Dr. Selwyn Ho, Chief Business Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on October 26, 2021, at 1:00 PM ET. A webcast of the discussion will be available on the Company's Investor Relations page, with a replay accessible afterward. Connect Biopharma focuses on developing therapies for chronic inflammatory diseases, with lead candidates CBP-201 and CBP-307 currently in clinical trials for conditions like atopic dermatitis and ulcerative colitis.
Connect Biopharma (Nasdaq: CNTB) announced the dosing of the first subject in a Phase 2 trial for CBP-201, targeting chronic rhinosinusitis with nasal polyps (CRSwNP). This randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy of CBP-201 in reducing nasal polyp scores and congestion in patients inadequately controlled by current therapies. The study enrolls approximately 140 subjects across 60 sites globally. CBP-201 targets interleukin-4 receptor alpha and has shown promise in earlier trials for various inflammatory diseases.
Connect Biopharma (Nasdaq: CNTB) has initiated a pivotal trial in China for its drug CBP-201, targeting adults with moderate-to-severe atopic dermatitis. This multicenter, randomized trial will evaluate CBP-201's efficacy and safety, enrolling approximately 255 patients across 55 clinical sites. The trial involves a 16-week treatment phase followed by a 36-week maintenance period. Atopic dermatitis is increasingly prevalent in China, highlighting the need for effective treatments. Success in this trial could expedite patient access to CBP-201.
Connect Biopharma reported a net loss of RMB 942.5 million (USD 145.9 million) for H1 2021, a significant increase from RMB 75.2 million in the same period last year. The company completed its IPO in March 2021, raising approximately USD 204.5 million, boosting cash to RMB 2,025 million (USD 313.5 million). Key milestones include the completion of Phase 2 trials for CBP-201 in atopic dermatitis and asthma, with top-line data expected in Q4 2021. R&D expenses surged to RMB 217.8 million (USD 33.7 million), driven by increased clinical and personnel costs.
Connect Biopharma (Nasdaq: CNTB) announced it will report financial results for H1 ended June 30, 2021 after market close on August 31, 2021. A webcast and conference call to discuss the results will take place on September 1, 2021, at 8:30 am ET. The company is advancing therapies for chronic inflammatory diseases through T cell research. Their lead product candidates include CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis and Crohn’s disease. For more details, refer to their website.
Connect Biopharma (Nasdaq: CNTB) has appointed Jiang Bian as General Counsel & Chief Compliance Officer, effective August 20, 2021. Bian brings extensive experience from Guardant Health and Pieris Pharmaceuticals, focusing on legal issues in healthcare and biopharma. Additionally, Jean Liu has joined the Board of Directors as an Independent Director, contributing over 20 years of biotech experience. These appointments aim to strengthen executive leadership and support Connect Biopharma's growth strategy, particularly in developing therapies for chronic inflammatory diseases.
Connect Biopharma (Nasdaq: CNTB) announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:00 am ET. The event aims to discuss the company's advancements in therapies for chronic inflammatory diseases, including their lead products CBP-201 and CBP-307. A live webcast can be accessed on Connect Biopharma's Investor Relations page, with a replay available post-event. The company is dedicated to innovative T cell-driven research.
Connect Biopharma (Nasdaq: CNTB) has announced the first dosing of a subject in a Phase I clinical trial for CBP-174, a novel oral treatment for chronic inflammatory pruritus. This double-blind, placebo-controlled trial aims to assess safety, tolerability, and pharmacokinetics of CBP-174, targeting patients suffering from chronic itch, particularly those with atopic dermatitis. The trial follows promising preclinical results showing rapid relief from itching. CEO Zheng Wei emphasized the importance of addressing unmet needs in pruritus management, highlighting CBP-174's potential to complement existing therapies.